ELI LILLY & Co
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3025% above fair value
$1410.99−6.55 (-0.46%)
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly Zyprexa (olanzapine) by Year
Zyprexa (olanzapine) — Worldwide revenue YoY (%) [legacy] (%)
Eli Lilly Zyprexa (olanzapine): -93.0% in FY2024. No newer figure appears in the documents we track.
Latest, FY2024
-93.0%
Period ended Dec 31, 2024
Change on a year earlier
–
History
7 years
Since FY2017
Sources
7
Documents cited below
Where the FY2024 figure comes from
“|| Zyprexa (4) | 2.0 | 114.3 | 116.3 | 1,694.8 | (93)”
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zyprexa (olanzapine) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| FY2024 | Dec 31, 2024 | -93.0% | – | Form 10-K FY2024 (filed 2025-02-19) ↗ |
| FY2022 | Dec 31, 2022 | -22.0% | -28.0 pts | Form 10-K FY2022 (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 6.0% | +9.0 pts | Form 10-K FY2021 (filed 2022-02-23) ↗ |
| FY2020 | Dec 31, 2020 | -3.0% | +16.0 pts | Form 10-K FY2020 (filed 2021-02-17) ↗ |
| FY2019 | Dec 31, 2019 | -19.0% | +1.0 pts | Form 10-K FY2019 (filed 2020-02-19) ↗ |
| FY2018 | Dec 31, 2018 | -20.0% | +3.0 pts | Form 10-K FY2018 (filed 2019-02-19) ↗ |
| FY2017 | Dec 31, 2017 | -23.0% | – | Form 10-K FY2017 (filed 2018-02-20) ↗ |
Cite this data
StockData. (2026). Eli Lilly Zyprexa (olanzapine) (%), annual FY2017–FY2024 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-zyprexa-yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.